UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Shares Outstanding

Last Annual Value

51.34M

3-Year CAGR

12%

5-Year CAGR

7%

10-Year CAGR

4%

UB

Upstream Bio, Inc. Competitors Analysis of shares-outstanding

UPB · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
51.34M
12.2%N/AN/A 
37.79M
94.3%61.6%32.8%
22.50M
50.6%51.4%N/A
148.76M
17.8%9.2%N/A
171.59M
11.9%12.5%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
44.26M
31.4%N/AN/A
44.73M
5.3%N/AN/A
54.68M
1.8%N/AN/A
16.87M
10.0%6.7%6.1%
72.92M
12.4%14.5%N/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97